Resolution of the Expert council «Dysbiosis. Immediate and long-term consequences of microbiome disturbances and options for their correction with the help of probiotics» (from February 19, 2022)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

GORELOV A.V., Chairman of the Council, MD, professor, academician of RAS, professor of the Department of pediatric diseases, I.M. Sechenov First Moscow state medical university of the Ministry of Healthcare of Russia (Sechenov University), deputy director for research work of Central Scientific Research Institute of Epidemiology of Rospotrebnadzor (Moscow) ZAKHAROVA I.N., co-chairman of the Council, MD, professor, head of the Department of pediatrics named after academician G.N. Speransky, Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia (Moscow) KHAVKIN A.I., co-chairman of the Council, MD, professor, head of the Moscow Regional Center for Pediatric Gastroenterology and Hepatology, Scientific Research Clinical Institution of Childhood of the Ministry of Healthcare of the Moscow Region (Moscow) KAFARSKAYA L.I., MD, professor, head of the Department of microbiology and virology, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Moscow) USENKO D.V., MD, leading researcher at the clinical Department of infectious pathology, Central Research Institute of Epidemiology of Rospotrebnadzor (Moscow) BELMER S.V., MD, professor, academician of RANS, professor of the Department of hospital pediatrics No. 2 of the pediatric Faculty, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, full member of ESPGHAN (Moscow) KORNIENKO E.A., MD, professor, professor of the Department of pediatric diseases named after professor I.M. Vorontsov, Saint Petersburg State Pediatric Medical University of the Ministry of Healthcare of Russia (Saint Petersburg) PRIVOROTSKY V.F., MD, professor of the Department of pediatric diseases named after professor I.M. Vorontsov, Saint Petersburg State Pediatric Medical University of the Ministry of Healthcare of Russia (Saint Petersburg) KONDYURINA E.G., MD, professor, head of the Department of pediatrics of advanced training Faculty and occupational retraining of doctors, Novosibirsk State Medical University of the Ministry of Healthcare of Russia (Novosibirsk) PANFILOVA V.N., MD, associate professor of the Department of pediatrics of Institute of Postgraduate Education, Professor Voyno-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Healthcare of Russia (Krasnoyarsk) THAKUSHINOVA N.Kh., MD, associate professor, head of the Department of pediatric infectious diseases, Kuban State Medical University of the Ministry of Healthcare of Russia (Krasnodar) PLAKSINA A.N., PhD in Medicine, assistant of the Department of physical and rehabilitation medicine, Ural State Medical University of the Ministry of Healthcare of Russia (Yekaterinburg) RYCHKOVA O.A., MD, head of the Department of infectious diseases, allergology and immunology with a course of dermatovenereology and cosmetology, Tyumen State Medical University of the Ministry of Healthcare of Russia (Tyumen) PECHKUROV D.V., MD, professor, head of the Department of pediatric diseases, Samara State Medical University of the Ministry of Healthcare of Russia (Samara) NIZHEVICH A.A., MD, professor, professor of the Department of hospital pediatrics with the course of outpatient pediatrics, Bashkir State Medical University of the Ministry of Healthcare of Russia (Ufa) FAYZULLINA R.A., MD, professor, head of the Department of propaedeutics of childhood diseases and faculty pediatrics, Kazan State Medical University of the Ministry of Healthcare of Russia (Kazan)

Full Text

Restricted Access

About the authors

- -

References

  1. The Human Microbiome Project Data Coordination Center (HMPDACC). Microbiome analyses. URL: https://hmpdacc.org/hmp/micro_analysis/microbiome_analyses.php (date of access - 11.06.2022).
  2. Human Microbiome Project Consortium. A framework for human microbiome research. Nature. 2012; 486(7402): 215-21. https://dx.doi.org/10.1038/nature11209.
  3. Huttenhower C., Gevers D., Knight R. et al. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486(7402): 207-14. https://dx.doi.org/10.1038/nature11234.
  4. Eckburg P.B., Bik E.M., Bernstein C.N. et al. Diversity of the human intestinal microbial flora. Science. 2005; 308(5728): 1635-38. https://dx.doi.org/10.1126/science.1110591.
  5. Costello E.K., Lauber C.L, Hamady M. et al. Bacterial community variation in human body habitats across space and time. Science. 2009; 326(5960): 1694-97. https://dx.doi.org/10.1126/science.1177486.
  6. Koren O., Knights D., Gonzalez A. et al. A Guide to enterotypes across the human body: Meta-analysis of microbial community structures in human microbiome datasets. PLoS Comput Biol. 2013; 9(1): e1002863. https://dx.doi.org/10.1371/journal.pcbi.1002863.
  7. Qin J., Li R., Raes J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464(7285): 59-65. https://dx.doi.org/10.1038/nature08821.
  8. Rodriguez J.M., Murphy K., Stanton C. et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015; 26: 26050. https://dx.doi.org/10.3402/mehd.v26.26050.
  9. Ventura M., Milani C., Lugli G.A., van Sinderen D. Health benefits conferred by the human gut microbiota during infancy. Microb Biotechnol. 2019; 12(2): 243-48. https://dx.doi.org/10.1111/1751-7915.13334.
  10. Arrieta M.C., Stiemsma L.T., Amenyogbe N. et al. The intestinal microbiome in early life: Health and disease. Front Immunol. 2014; 5: 427. https://dx.doi.org/10.3389/fimmu.2014.00427.
  11. Arboleya S., Binetti A., Salazar N. et al. Establishment and development of intestinal microbiota in preterm neonates. FEMS Microbiol Ecol. 2012; 79(3): 763-72. https://dx.doi.org/10.1111/j.1574-6941.2011.01261.x.
  12. Nylund L., Satokari R., Salminen S., de Vos W.M.Intestinal microbiota during early life - impact on health and disease. Proc Nutr Soc. 2014; 73(4): 457-69. https://dx.doi.org/10.1017/S0029665114000627.
  13. Nuriel-Ohayon M., Neuman H., Koren 0. Microbial changes during pregnancy, birth, and infancy. Front Microbiol. 2016; 7: 1031. https://dx.doi.org/10.3389/fmicb.2016.01031.
  14. Selma-Royo M., Tarrazo M., Garcia-Mantrana I. et al. Shaping microbiota during the first 1000 days of life. Adv Exp Med Biol. 2019; 1125: 3-24. https://dx.doi.org/10.1007/5584_2018_312.
  15. Rezaie A., Buresi M., Lembo A. et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. Am J Gastroenterol. 2017; 112(5): 775-84. https://dx.doi.org/10.1038/ajg.2017.46.
  16. Broekaert I.J., Borrelli 0., Dolinsek J. et al. An ESPGHAN Position Paper on the use of breath testing in paediatric gastroenterology. J Pediatr Gastroenterol Nutr. 2022; 74(1): 123-37. https://dx.doi.org/10.1097/MPG.0000000000003245.
  17. Усенко Д.В., Горелов А.В., Одинцова В.Е. с соавт. Нарушение микробиоты кишечника в остром периоде инфекционной диареи у детей и сравнительная оценка влияния последующей терапии нифуроксазидом и препаратами группы цефалоспоринов. Инфекционные болезни. 2020; 3: 88-96. @@ Usenko D.V., Gorelov A.V., Odintsova V.E. et al. Impairments of the intestinal microbiota in the acute period of infectious diarrhea in children and comparative analysis of the effects of nifuroxazide and cephalosporins. Infektsionnyye bolezni = Infectious Diseases. 2020; 3: 88-96 (In Russ.)]. https://dx.doi.org/10.20953/1729-9225-2020-3-88-96.
  18. Guarino A., Ashkenazi S., Gendrel D. et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: Update 2014. J Pediatr Gastroenterol Nutr. 2014; 59(1): 132-52. https://dx.doi.org/10.1097/MPG.0000000000000375.
  19. World Health Organization. Antimicrobial resistance. URL: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (date of access - 11.06.2022).
  20. Mekonnen S.A., Merenstein D., Fraser C.M., Marco M.L. Molecular mechanisms of probiotic prevention of antibiotic-associated diarrhea. Curr Opin Biotechnol. 2020; 61: 226-34. https://dx.doi.org/10.1016/j.copbio.2020.01.005.
  21. McFarland L.V. Therapies on the horizon for Clostridium difficile infections. Expert Opin Investig Drugs. 2016; 25(5): 541-55. https://dx.doi.org/10.1517/13543784.2016.1161025.
  22. Hempel S., Newberry S.J., Maher A.R. et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012; 307(18): 1959-69. https://dx.doi.org/10.1001/jama.2012.3507.105
  23. Zeng W., Qi K., Ye M. et al. Gastrointestinal symptoms are associated with severity of coronavirus disease 2019: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022; 34(2): 168-76. https://dx.doi.org/10.1097/MEG.0000000000002072.
  24. Czepiel J., Drozdz M., Pituch H. et al. Clostridium difficile infection: Review. Eur J Clin Microbiol Infect Dis. 2019; 38(7): 1211-21. https://dx.doi.org/10.1007/s10096-019-03539-6.
  25. Sokol H., Pigneur B., Watterlot L. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105(43): 16731-36. https://dx.doi.org/10.1073/pnas.0804812105.
  26. Chiara Mentella M., Scaldaferri F., Pizzoferrato M. et al. Nutrition, IBD and gut microbiota: A review. Nutrients. 2020; 12(4): 944. https://dx.doi.org/10.3390/nu12040944.
  27. Loddo I., Romano C. Inflammatory bowel disease: Genetics, epigenetics, and pathogenesis. Front Immunol. 2015; 6: 551. https://dx.doi.org/10.3389/fimmu.2015.00551.
  28. Chen S.J., Liu X.W., Liu J.P. et al. Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. World J Gastroenterol. 2014; 20(28): 9468-75. https://dx.doi.org/10.3748/wjg.v20.i28.9468.
  29. Pimentel M., Lembo A. Microbiome and its role in irritable bowel syndrome. Dig Dis Sci. 2020; 65(3): 829-39. https://dx.doi.org/10.1007/s10620-020-06109-5.
  30. Ellen Kuenzig M., Fung S.G., Marderfeld L. et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: Systematic review. Gastroenterology. 2022; 162(4): 1147-59.e4. https://dx.doi.org/10.1053/j.gastro.2021.12.282.
  31. Wang J.W., Kuo Ch.-H., Kuo F.-Ch. Fecal microbiota transplantation: Review and update. J Formos Med Assoc. 2019; 118 Suppl 1: S23-S31. https://dx.doi.org/10.1016/j.jfma.2018.08.011.
  32. Guarner F., Sanders M.E., Eliakim R. et al. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. February 2017. URL: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf (date of access - 11.06.2022).
  33. MacKenzie D.A., Defernez M., Dunn W.B. et al. Relatedness of medically important strains of Saccharomyces cerevisiae as revealed by phylogenetics and metabolomics. Yeast. 2008; 25(7): 501-12. https://dx.doi.org/10.1002/yea.1601.
  34. Kelesidis T., Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol. 2012; 5(2): 111-25. https://dx.doi.org/10.1177/1756283X11428502.
  35. McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010; 16(18): 2202-22. https://dx.doi.org/10.3748/wjg.v16.i18.2202.
  36. Szajewska H., Guarino A., Hojsak I. et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2014; 58 (4): 531-39. https://dx.doi.org/10.1097/MPG.0000000000000320.
  37. Szajewska H., Kolodziej M., Zalewski B.M. Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children - a 2020 update. Aliment Pharmacol Ther. 2020; 51(7): 678-88. https://dx.doi.org/10.1111/apt.15659.
  38. Li Z., Zhu G., Li C., Lai H. Which probiotic is the most effective for treating acute diarrhea in children? A Bayesian network metaanalysis of randomized controlled trials. Nutrients. 2021; 13(12): 4319. https://dx.doi.org/10.3390/nu13124319.
  39. Farthing M., Salam M., Lindberg G. et al. Acute diarrhea in adults and children: a global perspective. World Gastroenterology Organisation Global guidelines. February 2012 URL: https://www.worldgastroenterology.org/UserFiles/file/guidelines/acute-diarrhea-english-2012.pdf (date of access - 11.06.2022)
  40. Cruchet S., Furnes R., Maruy A. et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015; 17(3): 199-216. https://dx.doi.org/10.1007/s40272-015-0124-6.
  41. Ивашкин В.Т., Абдулганиева Д.И., Алексеенко С.А. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков, пребиотиков, синбиотиков и обогащенных ими функциональных пищевых продуктов для лечения и профилактики заболеваний гастроэнтерологического профиля у детей и взрослых). Доступ: https://mcrbm.com/files/getlinkedfile/682 (дата обращения - 11.06.2022). @@ Ivashkin V.T., Abdulganieva D.I., Alekseenko S.A. Practical recommendations of the Scientific Community to Promote the Clinical Study of the Human Microbiome and the Russian Gastroenterological Association on the use of probiotics, prebiotics, synbiotics and functional foods enriched with them for the treatment and prevention of gastroenterological diseases in children and adults). URL: https://mcrbm.com/files/getlinkedfile/682 (date of access - 11.06.2022) (In Russ.)
  42. Szajewska H., Kotodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea. Aliment Pharmacol Ther. 2015; 42(7): 793-801. https://dx.doi.org/10.1111/apt.13344.
  43. Kabbani T.A., Pallav K., Dowd S.E. et al. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes. 2017; 8(1): 17-32. https://dx.doi.org/10.1080/19490976.2016.1267890.
  44. Swidsinski A., Loening-Baucke V., Swidsinski S. Tu1695 Saccharomyces boulardii prevents the antibiotic induced changes in colonic microbiota. Gastroenterology. 2013; 144(5): S-824. https://dx.doi.org/10.1016/S0016-5085(13)63059-0.
  45. Kullar R., Johnson S., McFarland L.V., Goldstein E.J.C. Potential roles for probiotics in the treatment of COVID-19 patients and prevention of complications associated with increased antibiotic use. Antibiotics (Basel). 2021; 10(4): 408. https://dx.doi.org/10.3390/antibiotics10040408.
  46. Malfertheiner P., Megraud F., O'Morain C.A. et al. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1): 6-30. https://dx.doi.org/10.1136/gutjnl-2016-312288.
  47. Cifuentes S.G., Prado M.B., Fornasini M. et al. Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy. Helicobacter. 2022; 27(2): e12870. https://dx.doi.org/10.1111/hel.12870.
  48. Cindoruk M., Erkan G., Karakan T. et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: A prospective randomized placebo-controlled double-blind study. Helicobacter. 2007; 12(4): 309-16. https://dx.doi.org/10.1111/j.1523-5378.2007.00516.x.
  49. Бельмер С.В., Корниенко Е.А., Волынец Г.В. с соавт. Диагностика и лечение хеликобактерной инфекции у детей. Рекомендации общества детских гастроэнтерологов, гепатологов, нутрициологов. В сборнике: Актуальные проблемы абдоминальной патологии у детей. Под общей редакцией проф. С.В. Бельмера и проф. Л.И. Ильенко. 2022; с. 178-191. @@ Belmer S.V., Kornienko E.A., Volynets G.V. et al. Diagnosis and treatment of Helicobacter pylori infection in children. Recommendations of the society of pediatric gastroenterologists, hepatologists, nutritionists. In the collection: Actual problems of abdominal pathology in children. Under the general editorship of prof. S.V. Belmer and prof. L.I. Ilyenko. 2022; pp. 178-191 (In Russ.)
  50. Клинические рекомендации. Язвенная болезнь желудка и/или двенадцатиперстной кишки. Союз педиатров России, Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии, Общероссийская общественная организация «Российская ассоциация детских хирургов», Автономная некоммерческая организация «Общество детских гастроэнтерологов, гепатологов и нутрициологов». 2021. Рубрикатор клинических рекомендаций Минздрава России. ID: 388. Доступ: https://cr.minzdrav.gov.ru/schema/388_2 (дата обращения - 11.06.2022). @@ Clinical guidelines. Peptic ulcer of the stomach and/or duodenum.Russian Union of Pediatricians, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy, Russian Association of Pediatric Surgeons, Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists. 2021.Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. ID: 359.URL: https://cr.minzdrav.gov.ru/schema/388_2 (date of access - 11.06.2022) (In Russ.)
  51. Shen J., Zuo Z.X., Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014; 20(1): 21-35. https://dx.doi.org/10.1097/01.MIB.0000437495.30052.
  52. Bjarnason I., Sission G., Hayee B. A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. Infammopharmacology. 2019; 27(3): 465-73. https://dx.doi.org/10.1007/s10787-019-00595-4.
  53. Nutrition in paediatric inflammatory bowel disease: A Position Paper on behalf of the Porto IBD Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018; 66(4): 687-708. https://dx.doi.org/10.1097/MPG.0000000000001896.
  54. Ford A.C., Quigley E.M.M., Lacy B.E. et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014; 109(10): 1547-61; quiz 1546, 1562. https://dx.doi.org/10.1038/ajg.2014.202.
  55. Choi C.H., Jo S.Y., Park H.J. et al. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011; 45(8): 679-83. https://dx.doi.org/10.1097/MCG.0b013e318204593e.
  56. Инструкция по медицинскому применению лекарственного препарата Энтерол. РУ: П N011277. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b482718c-49e6-4d59-9a8e-37a6e1 b4ec08&t= (дата обращения - 04.06.2022). @@ Patient information leaflet for use of the drug for medical application Enterol. Registration certificate: П N011277. 57 URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b482718c-49e6-4d59-9a8e-37a6e1b4ec08&t= (date of access -04.06.2022) (In Russ.)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies